Evaluation of the effect of oral clonidine and metoclopramide after laparoscopic cholecystectomy

Comparing the effect of oral clonidine and metoclopramide on intraoperative hemodynamic parameters, nausea, and vomiting after laparoscopic cholecystectomy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210919052515N4

Enrollment

Registered

2022-04-12

Start date

2022-05-22

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laparoscopic cholecystectomy. Postcholecystectomy syndrome

Interventions

Intervention 1: Intervention group: Patients will receive one tablet of oral clonidine of 200 micrograms (group 1), 90 minutes before induction. Clonidine will be provided by Tolid Darou pharmaceutica

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective laparoscopic cholecystectomy Patients with the physical status of one and two according to the American Society of Anesthesiology (ASA I and ASA II) Age 20 to 60 years

Exclusion criteria

Exclusion criteria: Hypertension Diabetic patients Cardiovascular diseases Asthma disease Allergy to clonidine and metoclopramide

Design outcomes

Primary

Measure	Time frame
Heart rate. Timepoint: During induction, 5 minutes, 10 minutes after intubation, during skin incision, 15 and 30 minutes after pneumonia, 30 minutes after pneumonia release. Method of measurement: Monitoring.;Systolic blood pressure. Timepoint: During induction, 5 minutes, 10 minutes after intubation, during skin incision, 15 and 30 minutes after pneumonia, 30 minutes after pneumonia release. Method of measurement: Monitoring.;Diastolic blood pressure. Timepoint: During induction, 5 minutes, 10 minutes after intubation, during skin incision, 15 and 30 minutes after pneumonia, 30 minutes after pneumonia release. Method of measurement: Monitoring.;Mean arterial pressure (MAP). Timepoint: During induction, 5 minutes, 10 minutes after intubation, during skin incision, 15 and 30 minutes after pneumonia, 30 minutes after pneumonia release. Method of measurement: Monitoring.;Nausea. Timepoint: At the end of surgery. Method of measurement: Yes/No.;Vomiting. Timepoint: At the end of surgery. Method of measurement: Yes/No.	—

Measure

Time frame

Heart rate. Timepoint: During induction, 5 minutes, 10 minutes after intubation, during skin incision, 15 and 30 minutes after pneumonia, 30 minutes after pneumonia release. Method of measurement: Monitoring.;Systolic blood pressure. Timepoint: During induction, 5 minutes, 10 minutes after intubation, during skin incision, 15 and 30 minutes after pneumonia, 30 minutes after pneumonia release. Method of measurement: Monitoring.;Diastolic blood pressure. Timepoint: During induction, 5 minutes, 10 minutes after intubation, during skin incision, 15 and 30 minutes after pneumonia, 30 minutes after pneumonia release. Method of measurement: Monitoring.;Mean arterial pressure (MAP). Timepoint: During induction, 5 minutes, 10 minutes after intubation, during skin incision, 15 and 30 minutes after pneumonia, 30 minutes after pneumonia release. Method of measurement: Monitoring.;Nausea. Timepoint: At the end of surgery. Method of measurement: Yes/No.;Vomiting. Timepoint: At the end of surgery. Method of measurement: Yes/No.

—

Secondary

Measure	Time frame
Complications. Timepoint: At the end of surgery. Method of measurement: Clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Naser Masoudi

Oroumia University of Medical Sciences

masoudi.n@umsu.ac.ir+98 44 3345 7286

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026